Edwards Lifesciences Corporation
Daniel J. Lippis (CVP, TAVR) sells EW shares
AI-generated summary
Daniel J. Lippis, CVP, TAVR, exercised options to acquire 619 shares of Common Stock for $44,988.92 and sold 619 shares of Common Stock for $64,530.75. Following these transactions, the insider directly held 40,033.9103 shares of Common Stock. The trades were executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2026.
Key facts
- Insider
- Daniel J. Lippis · CVP, TAVR
Rule 10b5-1 plan · adopted Feb 13, 2026
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | M · exercise or conversion of a derivativeFootnotes F1 | +619 | $72.68 | $44,988.92 | 40,652.9103 | Direct |
| Nov 10, 2026 | S · open-market saleFootnotes F1 | −619 | $104.25 | $64,530.75 | 40,033.9103 | Direct |
| Nov 10, 2026 | M · exercise or conversion of a derivativeEmployee Stock Option (Right to Acquire) | −619 | $0.00 | $0.00 | 2,476 | Direct |
Footnotes
- F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026.
Remarks: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.
More EW filings
- 144
Filed Nov 10, 2026
- 4
Filed Nov 9, 2026
- 4
Filed Nov 9, 2026
- 144
Filed Nov 9, 2026
- 144
Filed Nov 9, 2026
- 10-Q
Filed Nov 4, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.